Genomes are the information contained within each person’s DNA. Today, some 100,000 people have had their genomes read and that is expected to rise to a billion within 10 years. Genomics plc has built a database that can be used to identify relationships between genetic variation and human disease.
Using genetic data has the potential to reduce costs and improve the efficiency of pharmaceutical companies, ultimately making drugs cheaper for the NHS and its users.
Whole genome sequencing is becoming increasingly common, as costs fall sharply, and this development has the potential to transform many aspects of healthcare if the associated data challenges of scale and complexity can be overcome. Building on the world-leading expertise and broad experience of the founders, the company has a unique analytical platform for genomic sequence data analysis and interpretation. Genomic analysis will bring huge value to patients, clinicians, healthcare managers and pharmaceutical and biotech companies.
We were founded by four of the world’s leading genomic scientists:
Prof. Peter Donnelly, CEO
Prof. Gil Mcvean, Director
Dr. Chris Spencer
Dr. Gerton Lunter
Our vision is: to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram. We can help
• PHARMACEUTICAL & BIOTECH De-risk the drug development process e.g. by identifying which drugs are likely to be successful reducing unnecessary clinical trials.
• GOVERNMENT & HEALTHCARE PROVIDERS Transform healthcare provision for citizens/members e.g. by building tools that analyse complex datasets for new medical insight.
05-Oct-2017 Innovate UK success story
… selected by Innovate UK The company has been awarded two Department of Health SBRI (Small Business Research Initiative), grants, plus a follow-up award…
Genomics plc has grown from a staff of 1 to a team of over 30. The company won its first two SBRI contracts in 2014, with a follow-on award for a population-scale analysis project. We awarded Genomics plc just over £2 million as part of an SBRI competition run for us by Genomics England Ltd, our Department of Health company set up to deliver the 100,000 Genomes Project.
26-Nov-14 –Genomics Ltd has completed a £10.3 million fundraising… IP Group
Park End Street
|GENOMICS LIMITED||2014-01-10 - 2015-03-30|
- 4573 Biotechnology
- Company Number
- Public Limited Company
- Company Age
- 5 years
- January 10, 2014
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Year End
- January 31
- Accounts Due
- July 31, 2019
- Latest Accounts
- January 31, 2018
One of our developers, Andy Thomason, talks about genetic variation from a programmer's perspective https://t.co/qJkVH88dlN
A huge congratulations to the @Genomicsplc team members who tackled the Oxford Town and Gown last weekend (before a… https://t.co/rLwumPlgYi
RT @ewanbirney: It terms of "all in" modelling for PRS I think it's going to be really hard to beat the @Genomicsplc crew (@genemodeller et…
RT @ewanbirney: @GENES_PK @AlexTISYoung @cecilejanssens @genemodeller @Genomicsplc I've been v. impressed by the @Genomicsplc combined risk…
RT @ewanbirney: @GENES_PK @AlexTISYoung @cecilejanssens This goes to how you use genetics, and I much prefer the @genemodeller / @Genomicsp…
RT @skathire: #BoG19 @genemodeller describes resource that @Genomicsplc has built 👇🏽 Impressive. https://t.co/e77tFrZuZn
Our newest recruit to the Cambridge office @omnislip trying out one of the new Genomics plc umbrellas https://t.co/npuSTkC2UG
OpenSource projects GenomicsPLC has initiated or contributed to: weCall (https://t.co/y3EqnoVRoK), VariantKey (… https://t.co/yt5Seqhx2G
Lovely paper from @sbmontgom highlighting how pervasive eQTLs are, and the importance of colocalization when using… https://t.co/u99q5tH6BY